THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, August 08, 2022
The virology research on treatments and vaccinations is advancing to enhance health issue equity
FREMONT, CA: The development of new treatments and vaccinations is advancing at a previously impossible rate. Scientific, commercial, and community partners today must carefully coordinate their efforts to drive the discovery and development of antiviral treatments.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Over the past two years, the world of health and medicine has constantly evolved, driven by the necessity to address unmet medical requirements revealed during the COVID-19 pandemic. A physician with more than 25 years of expertise in virology research, Frank Duff, Gilead’s Senior Vice President of Virology Therapeutic Area, is in charge of Gilead’s virology clinical development team, which is working to create treatments for some of the most difficult viruses in existence. The team is committed to leading the next wave of virology innovation, with a focus on serving the needs of everyone, including those related to HIV, hepatitis, COVID-19, and other viruses.
The firm’s researchers have a long history of creating antiviral medications that have helped communities and individuals affected by some of the most difficult public health issues to make critical changes.
A new era in virological care will necessitate various diverse strategies, including the development of breakthrough drugs and creative development techniques; the evaluation of unmet medical requirements for people all over the world; and inclusive research and discoveries that enhance health equity. Additionally, views a critical need for ongoing scientific research that supports the creation of person-centred therapeutic choices.
By including community voices throughout the process, from planning to execution, looking at real-world and participant-reported results, researchers can ensure that science is person-centric. For instance, it has been collaborating with community-based advisers to contribute their expertise and unique perspectives to HIV prevention research initiatives. Additionally, the team is leading other cutting-edge initiatives that incorporate groups that have traditionally been underrepresented in clinical research, such as women, young people, people of colour, and members of the LGBTQ+ community. All individuals with unmet needs across many therapeutic areas and their healthcare practitioners will have choices and the information they need to make knowledgeable healthcare decisions. It is anticipated that global health challenges will worsen in the following years to come as nations and economies throughout the world become progressively more interconnected. They continue to make significant investments in the hunt for novel therapeutic approaches that could help a variety of patients.
The extensive knowledge of virology enables us to advance person-centred innovation to support meeting critical global needs. To combat viral outbreaks and pandemics, it is committed to promoting antiviral research that offers innovation for future generations.
More in News